Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma

Philippos Apolinario Costa,David T Tse,Pasquale Benedetto
DOI: https://doi.org/10.1093/oncolo/oyad346
2024-01-16
The Oncologist
Abstract:Abstract Background Lacrimal gland adenoid cystic carcinoma (LGACC) has historically been associated with a poor prognosis even with localized disease, with a survival of 56% at 5 years. In 1988, we treated the first patient with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC). Since then, we have used this protocol as the standard approach. We aim to analyze the outcomes of patients with LGACC treated with the protocol and compare them to a population-based cohort to assess if IACC can improve survival. Methods We prospectively assessed all non-metastatic patients with LGACC treated with IACC at a single institution between 1988 and 2021. For a comparison group, we identified all non-metastatic patients with LGACC treated with excision from the Surveillance, Epidemiology, and End Results (SEER) registry. We calculated disease-specific survival using the Kaplan-Meier and Cox proportional-hazards modeling methods. Results Thirty-five non-metastatic patients with LGACC treated with IACC were identified at a single institution, and 64 patients with non-metastatic LGACC treated with excision were identified in the SEER database. The 5- and 10-year disease-specific survival rates for patients treated with IACC were 84% (95%CI 71-97) and 76% (95%CI 60-92), respectively. While the 5- and 10-year disease-specific survival rates for the population-based cohort were 72% (95%CI 62-82) and 46% (95%CI 32-60). The survival analysis favored IACC, with a 60% lower risk of death (HR: 0.4; 95%CI 0.2-0.9). Conclusion IACC improves disease-specific survival in comparison to a population-based cohort treated with excision. Additional patients treated with IACC at multiple institutions are required to provide further external validity.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is that patients with Lacrimal Gland Adenoid Cystic Carcinoma (LGACC) have a poor prognosis. Even in the case of local diseases, the 5 - year survival rate is only 56%. Since 1988, the research team has begun to use Neoadjuvant Intra - arterial Cytoreductive Chemotherapy (IACC) to treat LGACC patients and has made it a standard treatment method. This study aims to analyze the prognosis of LGACC patients receiving IACC treatment, compare it with the population - based cohort, and evaluate whether IACC can improve the survival rate. Specifically, the researchers hope to verify whether IACC can improve the disease - specific survival rate of LGACC patients by comparing the patients receiving IACC treatment with the patient group only receiving surgical resection. The research methods include prospectively evaluating all non - metastatic LGACC patients who received IACC treatment in a single institution between 1988 and 2021, and identifying all non - metastatic LGACC patients who received surgical resection from the Surveillance, Epidemiology, and End Results (SEER) registry as the control group. The disease - specific survival rate was calculated by Kaplan - Meier and Cox proportional hazards model methods. The research results show that the 5 - year and 10 - year disease - specific survival rates of patients receiving IACC treatment are 84% (95%CI 71 - 97) and 76% (95%CI 60 - 92) respectively, while the 5 - year and 10 - year disease - specific survival rates of the population - based control group are 72% (95%CI 62 - 82) and 46% (95%CI 32 - 60) respectively. Survival analysis shows that IACC reduces the risk of death by 60% (HR: 0.4; 95%CI 0.2 - 0.9). The conclusion is that compared with the population - based control group, IACC can significantly improve the disease - specific survival rate of LGACC patients. In the future, more research needs to be carried out in multiple institutions to further verify the effectiveness of this strategy.